GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Merus NV (NAS:MRUS) » Definitions » Cyclically Adjusted Price-to-FCF

Merus NV (Merus NV) Cyclically Adjusted Price-to-FCF : (As of Jun. 07, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Merus NV Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Merus NV Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Merus NV's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merus NV Cyclically Adjusted Price-to-FCF Chart

Merus NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Merus NV Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Merus NV's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Merus NV's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merus NV's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Merus NV's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Merus NV's Cyclically Adjusted Price-to-FCF falls into.



Merus NV Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Merus NV's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Merus NV's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.765/128.5800*128.5800
=-0.765

Current CPI (Mar. 2024) = 128.5800.

Merus NV Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.000 99.240 0.000
201409 0.000 99.960 0.000
201412 0.000 99.050 0.000
201503 -0.313 99.750 -0.403
201506 -0.283 100.230 -0.363
201509 -0.545 100.500 -0.697
201512 -0.500 99.730 -0.645
201603 -0.537 100.310 -0.688
201606 -0.515 100.260 -0.660
201609 -0.331 100.570 -0.423
201612 -0.521 100.710 -0.665
201703 -0.384 101.440 -0.487
201706 -0.582 101.370 -0.738
201709 -0.788 102.030 -0.993
201712 -0.620 101.970 -0.782
201803 -0.775 102.470 -0.972
201806 -0.091 103.100 -0.113
201809 -0.835 103.950 -1.033
201812 -0.576 103.970 -0.712
201903 -0.604 105.370 -0.737
201906 -0.689 105.840 -0.837
201909 -0.657 106.700 -0.792
201912 -0.751 106.800 -0.904
202003 -0.878 106.850 -1.057
202006 -0.653 107.510 -0.781
202009 -0.414 107.880 -0.493
202012 -0.826 107.850 -0.985
202103 0.530 108.870 0.626
202106 -0.636 109.670 -0.746
202109 -0.606 110.790 -0.703
202112 -0.771 114.010 -0.870
202203 -1.075 119.460 -1.157
202206 -0.793 119.050 -0.856
202209 -0.946 126.890 -0.959
202212 -0.704 124.940 -0.725
202303 -0.871 124.720 -0.898
202306 -0.868 125.830 -0.887
202309 -0.512 127.160 -0.518
202312 -0.628 126.450 -0.639
202403 -0.765 128.580 -0.765

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Merus NV  (NAS:MRUS) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Merus NV Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Merus NV's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Merus NV (Merus NV) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Merus NV (NAS:MRUS) » Definitions » Cyclically Adjusted Price-to-FCF
Traded in Other Exchanges
Address
Uppsalalaan 17, Utrecht, NLD, 3584 CT
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
Executives
Harry Shuman officer: Chief Accounting Officer C/O MERUS N.V., VALELAAN 62, UTRECHT P7 3584 CM
Peter B. Silverman officer: EVP & General Counsel C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM
Sven Ante Lundberg director, officer: President, CEO & PFO C/O CRISPR THERAPEUTICS AG, 200 SIDNEY STREET, CAMBRIDGE MA 02139
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Kruif John De officer: Chief Technology Officer C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM
Paolo Pucci director C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Len Kanavy director C/O MERUS N.V., VALELAAN 62, UTRECHT P7 3584 CM
Maxine Gowen director
Anand Mehra director 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Victor Sandor director C/O ARRAY BIOPHARMA INC., 3200 WALNUT STREET, BOULDER CO 80301
Mark T Iwicki director 84 WATERFORD DRIVE, MARLBOROUGH MA 01752
Gregory D Perry director C/O IMMUNOGEN, INC., 830 WINTER ST., WALTHAM MA 02451
Geuijen Cecile A W officer: SVP & Chief Scientific Officer C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584CM
Andrew Joe officer: SVP, CMO C/O MERUS N.V., VALELAAN 62, UTRECHT P7 3584 CM
Mark Throsby officer: EVP & Chief Scientific Officer C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM